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Abstract
The EphB4 receptor tyrosine kinase together with its preferred ligand, ephrin-B2, regulates a variety of physiological and
pathological processes, including tumor progression, pathological forms of angiogenesis, cardiomyocyte differentiation and
bone remodeling. We previously reported the identification of TNYL-RAW, a 15 amino acid-long peptide that binds to the
ephrin-binding pocked of EphB4 with low nanomolar affinity and inhibits ephrin-B2 binding. Although ephrin-B2 interacts
promiscuously with all the EphB receptors, the TNYL-RAW peptide is remarkably selective and only binds to EphB4.
Therefore, this peptide is a useful tool for studying the biological functions of EphB4 and for imaging EphB4-expressing
tumors. Furthermore, TNYL-RAW could be useful for treating pathologies involving EphB4-ephrin-B2 interaction. However,
the peptide has a very short half-life in cell culture and in the mouse blood circulation due to proteolytic degradation and
clearance by the kidneys and reticuloendothelial system. To overcome these limitations, we have modified TNYL-RAW by
fusion with the Fc portion of human IgG1, complexation with streptavidin or covalent coupling to a 40 KDa branched
polyethylene glycol (PEG) polymer. These modified forms of TNYL-RAW all have greatly increased stability in cell culture,
while retaining high binding affinity for EphB4. Furthermore, PEGylation most effectively increases peptide half-life in vivo.
Consistent with increased stability, submicromolar concentrations of PEGylated TNYL-RAW effectively impair EphB4
activation by ephrin-B2 in cultured B16 melanoma cells as well as capillary-like tube formation and capillary sprouting in co-
cultures of endothelial and epicardial mesothelial cells. Therefore, PEGylated TNYL-RAW may be useful for inhibiting
pathological forms of angiogenesis through a novel mechanism involving disruption of EphB4-ephrin-B2 interactions
between endothelial cells and supporting perivascular mesenchymal cells. Furthermore, the PEGylated peptide is suitable
for other cell culture and in vivo applications requiring prolonged EphB4 receptor targeting.
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Introduction
EphB4 is a member of the large Eph receptor tyrosine kinase
family. Eph receptors have been implicated in a wide variety of
physiological and pathological processes, and are therefore
considered promising drug target candidates [1]. The EphB4
receptor preferentially binds the transmembrane ligand, ephrin-
B2, at sites of cell-cell contact. The interaction initiates
bidirectional cellular responses through both EphB4 (‘‘forward’’
signals) and ephrin-B2 (‘‘reverse’’ signals).
EphB4 is highly expressed in most cancer cell types, including
prostate, breast, ovarian, colorectal, lung and bladder cancers,
melanoma and mesothelioma [2,3,4,5,6,7,8]. EphB4-ephrin-B2
bidirectional signaling appears to promote the malignancy of
certain cancers, such as melanoma [9,10,11]. However, the role of
the EphB4/ephrin-B2 system in other cancer cell types is
controversial [1,2,4,7,12].
EphB4-ephrin-B2 interaction is also known to play a critical role
in angiogenesis, including blood vessel remodeling during embry-
onic development, tumor vascularization and other forms of
pathological angiogenesis [2,13,14]. Ephrin-B2 is widely expressed
in tumor blood vessels, where it is upregulated by hypoxia and
vascular endothelial growth factor (VEGF). Ephrin-B2 reverse
signaling, triggered by contact with EphB4 and other EphB
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example, it promotes the migration/invasion and proliferation/
survival of cultured endothelial cells [15,16,17]. In addition, recent
studies have shown that ephrin-B2 reverse signaling is required for
vascular endothelial growth factor (VEGF) receptor internalization
in endothelial cells, which is critical for VEGF-dependent
angiogenesis [18,19]. Ephrin-B2 reverse signaling also plays an
important role in perivascular mesenchymal cells, including
pericytes and vascular smooth muscle cells, and regulates their
association with endothelial cells in vivo leading to vessel maturation
and stabilization [20,21]. Thus, an important role of EphB4 during
tumor progression is to promote ephrin-B2 reverse signaling in the
vasculature. This role may be fulfilled by EphB4 present in tumor
cells or co-expressed in vascular cells [13,14,15,22]. Additionally,
ephrin-B2-induced EphB4 forward signaling in endothelial cells
likely contributes to tumor angiogenesis [13,14,16,19,23,24].
The interaction between EphB4 expressed in circulating tumor
cells and ephrin-B2 expressed in endothelial cells has also been
reported to mediate site-specific metastatic dissemination [8]. Other
roles of EphB4-ephrin-B2 bidirectional signaling include regulation
of bone remodeling [25] and cardiomyocyte differentiation [26,27].
Inhibiting EphB4-ephrin-B2 interaction could therefore be
useful for diverse medical applications. For example, administra-
tion of soluble monomeric EphB4 extracellular domain, which
interferes with the binding of ephrin-B2 to EphB receptors and
inhibits bidirectional signaling, was shown to inhibit tumor growth
and tumor angiogenesis in several mouse tumor xenograft
models as well as neovascularization in a model of retinopathy
[28,29,30,31,32]. A 15 amino acid-long EphB4 antagonistic
peptide, TNYL-RAW (TNYLFSPNGPIARAW), could represent
an alternative to the large EphB4 extracellular domain. TNYL-
RAW is a modified version of a 12 amino acid-long peptide
identified by phage display [33]. It binds to EphB4 with
remarkably high affinity (KD of 3 nM for mouse EphB4 as
measured by surface plasmon resonance [34] and 70 nM for
human EphB4 as measured by isothermal titration calorimetry
[35]). TNYL-RAW binds in the hydrophobic pocket that
represents the high affinity binding site for ephrin-B2 and
selectively binds to EphB4 but not any other Eph receptor [33,35].
The TNYL-RAW peptide has been shown to inhibit EphB4
tyrosine phosphorylation (activation) induced by ephrin-B2 in
cultured MCF7 breast cancer cells [33] and human umbilical vein
endothelial cells (HUVECs) [36]. Furthermore, it inhibits ephrin-
B2-induced retraction of HUVECs and capillary-like tube
formation on Matrigel [21,36,37]. Hence, this peptide could be
useful to inhibit EphB4 pathological activities.
Here we show that, like many other peptides, TNYL-RAW is
rapidly lost from cell culture medium and when administered in
vivo. This limits its possible research, therapeutic and diagnostic
applications. Therefore, we have investigated approaches to
increase its half-life in cell culture and in vivo. These studies
identify PEGylated TNYL-RAW as an improved form of the
peptide that retains high binding affinity for EphB4 but has greatly
decreased susceptibility to proteolytic degradation and increased
permanence in the mouse blood circulation. Importantly,
PEGylation is a modification compatible with the use of TNYL-
RAW for preclinical as well as clinical studies.
Results
The TNYL-RAW peptide has a short half-life in cell culture
medium and in the mouse circulation
We previously reported that the TNYL-RAW peptide inhibits
EphB4-ephrin-B2 binding with an IC50 value of ,15 nM in
ELISA assays [33]. However, much higher peptide concentrations
(10–100 mM) are needed to substantially inhibit ephrin-B2-
induced EphB4 tyrosine phosphorylation and downstream effects
in cultured cells [21,26,33,36,37]. An explanation for the
discrepancy in the potency of the peptide in biochemical and cell
culture assays could be that TNYL-RAW is susceptible to
degradation by proteases present in cell culture medium. For
example, trypsin-like proteases are likely to cleave the peptide
between R13 and A14 [38]. The consequent loss of W15, which is
involved in multiple interactions with the ephrin-binding pocket of
EphB4 [35], would be expected to result in a dramatic decrease in
affinity.
To assess the half-life of TNYL-RAW in cell culture, a
biotinylated form of the peptide was incubated with PC3 prostate
cancer cells that had been grown in the same medium for several
days. The amount of intact TNYL-RAW remaining after different
incubation times was measured in ELISA assays by capturing
the peptide with immobilized EphB4 Fc and detecting it
with streptavidin conjugated to horseradish peroxidase (HRP).
TNYL-RAW was rapidly lost in PC3 cell culture medium, with
half-lives varying from less than an hour to several hours
depending on cell density and how long the cells had been grown
in the culture medium (Figure 1A and data not shown). Moreover,
when incubated with cells in fresh culture medium, TNYL-RAW
had a longer half-life (Figure 1A), suggesting that its loss is due to
degradation by proteases produced by the cells and accumulating
in the culture medium rather than uptake by the cells or other
mechanisms. Supporting the idea of proteolytic degradation,
TNYL-RAW loss was also observed in conditioned medium
without the cells (Figure 1B) and was blocked by a mixture of
protease inhibitors (Figure 1B). Incubation in PC3 cell conditioned
medium for several hours also abolished the ability of TNYL-
RAW to inhibit ephrin-B2-EphB4 interaction in ELISA assays
(Figure 1C), confirming that the peptide itself is cleaved rather
than just losing the biotin tag used for detection. Rapid TNYL-
RAW loss was also observed in all other cell types examined,
including B16 melanoma cells, human umbilical vein endothelial
cells (HUVECs) and epicardial mesothelial cells (EMCs) (Figure
S1) as well as C6 glioma cells and BPH1 prostate epithelial cells
(data not shown). TNYL-RAW is also very rapidly lost from the
mouse circulation and in our ELISA assay it could not be detected
in serum as early as 30 min after intravenous administration
(Figure 1D). This may be at least in part due to proteolytic
degradation because TNYL-RAW is also rapidly lost when
incubated ex vivo at 37uC in mouse serum, an effect that can be
partially counteracted by a mixture of protease inhibitors (Fig. 1E).
Some peptide loss also occurs at room temperature during the
ELISA assay, since less peptide is detected at the 0 time point in
the absence of protease inhibitors.
Modified forms of TNYL-RAW retain high EphB4 binding
affinity
We investigated several modifications that might improve the
resistance of the TNYL-RAW peptide to proteolytic degradation
and increase its half-life in the blood circulation. We generated
TNYL-RAW fused to the Fc portion of human IgG1 by
purification from the culture medium of transiently transfected
293 human embryonal kidney (HEK) cells, because Fc fusion
proteins typically have increased resistance to proteolysis and a
long half-life in vivo [39,40]. We also modified the biotinylated
synthetic TNYL-RAW by complexation with streptavidin or by
covalent coupling to a 40 KDa branched PEG polymer.
Streptavidin is a bacterial tetrameric protein of approximately
50 KDa that binds biotin with very high affinity and has also
PEGylated Antagonistic Peptide Targeting EphB4
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PEG molecules is a modification often used in the pharmacolog-
ical industry to decrease proteolytic degradation and in vivo
clearance of peptides, proteins and small molecules [40,43]. To
minimize possible negative effects of the large branched PEG
molecule on the ability of TNYL-RAW to bind EphB4, we
attached it to the N terminus of TNYL-RAW, because the N-
terminal T1 and N2 amino acids are not involved in the
interaction with EphB4 [35]. By measuring TNYL-RAW binding
to immobilized EphB4 or EphB4 binding to immobilized TNYL-
RAW in ELISA assays, we confirmed that the binding affinity of
all three modified forms of the peptide is not substantially affected
compared to the unmodified biotinylated peptide (Figure 2A,B).
The apparent increase in affinity observed for TNYL-RAW
bound to streptavidin or fused to Fc is likely due to the
multimeric nature of these molecules, because TNYL-RAW-Fc is
a dimer and TNYL-RAW-streptavidin is a tetramer. ELISA
competition experiments further confirmed that none of the
modifications substantially affects the ability of TNYL-RAW to
inhibit EphB4-ephrin-B2 binding (Figure 2C). Therefore, the
TNYL-RAW peptide fused to Fc, bound to streptavidin or
covalently coupled to 40 KDa PEG remains a potent EphB4
antagonist.
Modified forms of TNYL-RAW have increased half-life in
cell culture medium and mouse blood
Fusion to Fc, complexation with streptavidin and PEGylation
all dramatically improve the half-life of TNYL-RAW in cell
culture medium, as indicated by the absence of peptide
degradation after incubation in PC3 cell conditioned medium
for up to 48 hours (Figure 3A) and much decreased degradation
after incubation in mouse serum (Figure 3B). Of note, TNYL-
RAW-Fc was not as stable in mouse serum as the streptavidin-
bound or PEGylated peptide. The three modifications also
increased the persistence of TNYL-RAW in the mouse blood
circulation after intravenous injection. While TNYL-RAW was
undetectable in serum prepared from blood collected 30 min
after peptide injection (Figure 1D), the circulation half-life of
TNYL-RAW-Fc and TNYL-RAW-streptavidin was ,1h o u r
(area under the curve (AUC)=140% and 110% of the injected
doseNhours/ml, respectively) and the half-life of intravenously
injected PEG-TNYL-RAW was ,11 hours (AUC=790% of the
injected doseNhours/ml) (Figure 3C). We also found that even
though as expected PEG-TNYL-RAW injected intraperitoneally
enters the circulation more slowly than the peptide injected
intravenously, it nevertheless reaches similar blood levels after 6
and 24 hours (Figure 3C, right panel). Thus, intraperitoneal
injection can be used as a more convenient route of administra-
tion for in vivo studies.
PEGylated TNYL-RAW inhibits EphB4 and ephrin-B2
phosphorylation in cells
Consistent with its greatly improved half-life in cell culture
medium, PEG-TNYL-RAW inhibits ephrin-B2-induced tyrosine
phosphorylation of endogenous EphB4 expressed in B16 melano-
ma cells with an IC50 value of 90 nM, and 2 mM peptide are
sufficient to reduce receptor phosphorylation to undetectable levels
(Figure 4A, B). Furthermore, PEG-TNYL-RAW but not the
unmodified peptide, retains its inhibitory activity even after
24 hours of incubation with B16 cells (Figure 4A). Prolonged
incubation with PEG-TNYL-RAW also inhibits endogenous
EphB4 phosphorylation in mixed cultures of epicardial mesothelial
cells (EMCs) and human umbilical vein endothelial cells
(HUVECs), two cell types that express both EphB4 and ephrin-
Figure 1. The TNYL-RAW peptide is rapidly lost in cell culture medium and from the mouse circulation. (A) Biotinylated TNYL-RAW
peptide was incubated with cultured PC3 prostate cancer cells grown in the same medium for 3 days or in the culture medium freshly replaced just
before adding the peptide. Functional (EphB4- and streptavidin-binding) peptide remaining at the indicated times was captured in ELISA plates
coated with EphB4 Fc and detected with streptavidin-HRP. (B) TNYL-RAW was incubated at 37uC in PC3 cell conditioned medium (without cells) with
and without a mixture of protease inhibitors including aprotinin, leupeptin, pepstatin and PMSF, and detected as in (A). (C) TNYL-RAW was incubated
with PC3 cell conditioned medium for 4 hours and added together with ephrin-B2 AP to ELISA wells pre-coated with EphB4 Fc. TNYL-RAW mixed with
conditioned medium right before the ELISA assay (0 hrs) was used as a control. The graph shows the ratio of ephrin-B2 AP bound in the presence and
in the absence of peptide. (D) Serum from 3 mice injected intravenously with 6 nmoles biotinylated TNYL-RAW was collected 30 min after peptide
administration and incubated at a dilution of 1:20 in ELISA wells pre-coated with EphB4 Fc. Based on the amount of injected TNYL-RAW and an
estimated mouse serum volume of 2.5 ml, the peptide concentration in the wells would be 120 nM. TNYL-RAW at a concentration of 5 nM in similarly
diluted mouse serum was used for comparison. Bound peptide was detected with streptavidin-HRP. (E) TNYL-RAW was incubated in undiluted mouse
serum ex vivo for the indicated times and detected as described in (A). Averages from 3 measurements 6 SE are shown in all the panels.
doi:10.1371/journal.pone.0028611.g001
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structures when cultured together on Matrigel [44,45,46] (see
below). Interestingly, the peptide also inhibits tyrosine phosphor-
ylation of ephrin-B2 induced by treatment of EMCs and HUVECs
with EphB4 Fc, a soluble dimeric form of the EphB4 extracellular
domain fused to Fc that should preferentially activate ephrin-B2
among the ephrin-B ligands (Figure 4E). Ephrin-B2 phosphory-
lation was measured by immunofluorescence microscopy using a
phospho-ephrin-B antibody, which performed better in this type of
assay than in immunoblotting experiments. Thus, PEG-TNYL-
RAW can be used to inhibit both forward and reverse signals
generated by the EphB4-ephrin-B2 complex.
Low micromolar concentrations of PEGylated TNYL-RAW
inhibit capillary-like tube formation and capillary
sprouting
Ephrin-B2 reverse signaling has been shown to play an
important role in the interaction between endothelial cells and
vascular mural cells such as pericytes and smooth muscle cells
[20,21,30,31]. EMCs express smooth muscle actin (Figure S2) and
after 20 hours on Matrigel form capillary-like structures together
with HUVECs, as expected for vascular support cells (Figure 5).
We found that PEG-TNYL-RAW at a concentration of 5 mM
disrupts the tubular organization of the mixed endothelial-mural
cell structures (Figure 5), whereas the PEG control had no effect
Figure 2. Modified forms of TNYL-RAW retain high EphB4 binding affinity and potency for inhibition of EphB4-ephrin-B2 binding.
(A) Biotinylated, streptavidin-bound and PEGylated TNYL-RAW were incubated at the indicated concentrations in EphB4-coated ELISA wells.
Biotinylated TNYL-RAW was detected with streptavidin-HRP, TNYL-RAW-streptavidin was detected with and anti-streptavidin antibody coupled to
HRP, and PEG-TNYL-RAW was detected with an anti-PEG antibody followed by a secondary antibody conjugated to HRP. (B) The indicated
concentrations of EphB4 AP were incubated in ELISA wells pre-coated with streptavidin and biotinylated TNYL-RAW (left) or an anti-IgG antibody and
TNYL-RAW-Fc (right). Kd values are based on EphB4 AP concentrations calculated from AP activity. (C) The different forms of TNYL-RAW were
incubated at the indicated concentrations together with a constant amount of ephrin-B2 AP in ELISA wells pre-coated with EphB4 Fc. The ratio of
ephrin-B2 AP bound in the presence and in the absence of peptide is shown. The graphs show averages 6 SE from triplicate measurements in
representative experiments, while the Kd and IC50 values are calculated from 3 to 11 experiments.
doi:10.1371/journal.pone.0028611.g002
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also effective at submicromolar concentrations, whereas unmod-
ified TNYL-RAW does not have significant effects at the
concentrations tested (up to 20 mM; Figure 6). Interestingly,
although both HUVECs and EMCs can also form capillary-like
tubes on Matrigel when cultured individually, TNYL-RAW did
not significantly affect the integrity of these structures (Figure 5),
which excludes non-specific toxic effects of the peptide on the cells.
Notably, EMCs form tubes more rapidly than HUVECs, but their
tubes spontaneously disintegrate by 15–20 hours in the absence of
co-cultured HUVECs. PEG-TNYL-RAW also reduced the
capillary sprouts formed over a period of two days by spheroids
containing both HUVECs and EMCs and embedded in a collagen
gel (Figure 7). These effects imply that EphB4 is a particularly
important partner for ephrin-B2 in the interplay between
endothelial and mural cells and suggest that the TNYL-RAW
peptide can be used to effectively inhibit angiogenic responses
involving the two cell types.
Discussion
Peptides are known to have a short half-life in cell culture or
when systemically administered in vivo, mainly due to proteolytic
degradation and clearance by the kidneys and reticuloendothelial
system [40,43,47,48]. We indeed found that the EphB4-targeting
peptide, TNYL-RAW, is rapidly lost in cell culture medium and in
the mouse blood circulation. This is in agreement with the blood
pharmacokinetic studies reported for
64Cu-DOTA-TNYL-RAW
in a recent study [49]. In cell culture, TNYL-RAW is degraded by
proteases secreted by the cells because peptide loss is delayed in
freshly replaced cell culture medium and addition of protease
inhibitors blocks its degradation in conditioned medium. Degra-
dation by proteases may also contribute to TNYL-RAW loss in
vivo, as suggested by the rapid loss of the peptide incubated in
mouse serum ex vivo [43,50]. The biodistribution data reported for
TNYL-RAW coupled to
64Cu-DOTA or polymeric micellar
nanoparticles suggest that uptake by the spleen and liver and
Figure 3. Modified forms of TNYL-RAW have increased stability in cell culture medium and in the mouse circulation. (A, B)
Biotinylated, streptavidin-bound, fused to Fc and PEGylated TNYL-RAW were incubated in medium conditioned by PC3 prostate cancer cells (A) or
mouse serum (B). Functional peptide remaining at the indicated times was captured in ELISA plates and quantified. Biotinylated TNYL-RAW was
captured on ELISA wells pre-coated with EphB4 Fc and detected with Streptavidin-HRP. TNYL-RAW-streptavidin was captured on wells pre-coated
with EphB4 Fc and detected with an anti-streptavidin antibody coupled to HRP. TNYL-RAW-Fc was captured on wells coated with an anti-Fc antibody
and detected with EphB4 AP. PEG-TNYL-RAW was captured on wells coated with EphB4 Fc and detected with anti-PEG antibody followed by a
secondary antibody conjugated to HRP. Normalized averages from 6–9 measurements 6 SE are shown. Peptide amounts at different time points
were compared to those at time 0 by one-way ANOVA and Dunnett’s post test. *P,0.05, **P,0.001 and ***P,0.001. (C) Blood from mice injected
intravenously (IV) or intraperitoneally (IP) with 2.1 nmoles TNYL-RAW-Fc, 1.5 nmoles TNYL-RAW-streptavidin or 6 nmoles of PEG-TNYL-RAW was
collected and peptide levels in the serum were measured in ELISA assays as described in (A). Peptide concentrations in serum were calculated based
on a standard curve generated using serum containing known TNYL-RAW concentrations. Areas under the curve (AUC) values were calculated as
described in the Materials and Methods. Averages from blood collected from 3 mice 6 SE are shown.
doi:10.1371/journal.pone.0028611.g003
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indicated concentrations of PEG-TNYL-RAW or TNYL-RAW for 15 min or 24 hours were stimulated with 1.5 mg/ml preclustered ephrin-B2 Fc (+)o rF c
as a control (2) for 20 min in the continued presence of the peptide. EphB4 immunoprecipitates were probed with anti-phosphotyrosine antibody
(PTyr) and reprobed for EphB4. (B) The inhibition curve shows the relative levels of EphB4 phosphorylation in the presence of different concentrations
of PEG-TNYL-RAW, which were quantified from immunoblots and normalized to the amount of immunoprecipitated EphB4. Error bars represent the
standard error from 3–6 experiments. (C) HUVEC and EMC lysates were probed for EphB4, ephrin-B2 (band at ,45 Kd detected with a pan-ephrin-B
antibody) and ß-actin as a loading control. It is not known why the ephrin-B2 band appears as a more prominent doublet in EMCs than HUVECs. (D)
HUVECs and EMCs were cultured individually or mixed at a 1:1 ratio in the presence of 1.5 mM PEG-TNYL-RAW or PEG control. EphB4
immunoprecipitates were probed with an anti-phosphotyrosine antibody (PTyr) and reprobed for EphB4. (E) HUVECs and EMCs, which express EGFP,
were cultured at a 1:1 ratio for 15 hours in the presence of 1.5 mM PEG-TNYL-RAW or PEG control. The cells were then stimulated with 1.5 mg/ml
preclustered EphB4 Fc or Fc as a control for 20 min in the continued presence of the peptide or PEG. The cells were stained for phospho-ephrin-B
(red), which likely corresponds to the phosphorylated form of the EphB4 preferred ligand ephrin-B2, and nuclei were labeled with DAPI (blue). Scale
bar=50 mM. Fluorescence intensity from 6 micrographs per condition was quantified. The values obtained (expressed in arbitrary units 6 standard
error) are: PEG & Fc, 2462.6; PEG & EphB4 Fc, 4463.6; PEG-TNYL-RAW & EphB4 Fc, 2062.5. The fluorescence of cells treated with PEG-TNYL-RAW &
EphB4 Fc was significantly (P,0.001) different from that of cells treated with PEG & EphB4 Fc, but not from that of cells treated with PEG & Fc, by one-
way ANOVA and Bonferroni’s post test.
doi:10.1371/journal.pone.0028611.g004
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the blood circulation [34,49].
Despite the low nanomolar EphB4 binding affinity of TNYL-
RAW, the very short half-life of the peptide greatly limits its
effectiveness, as exemplified by the high concentrations (10–
100 mM) needed to inhibit EphB4-ephrin-B2 interaction in cell
culture [21,33,36,37]. We used three strategies to improve TNYL-
RAW stability in cell culture and circulating half-life: fusion with
Fc, complexation with streptavidin and covalent coupling to
40 KDa polymeric PEG molecules. Fusion with Fc has been
successfully used to improve the stability and pharmacokinetic
properties of numerous proteins and peptides, and a number of
drugs approved for human use contain an Fc moiety [39,40,51].
Streptavidin has been used in preclinical and human clinical
studies as part of tumor-targeting delivery systems, however it
cannot be administered multiple times because of its high
Figure 5. PEGylated TNYL-RAW inhibits capillary-like tube formation in co-cultured HUVECs and EMCs. EMCs expressing EGFP and
cultured in DMEM or complete Medium 200 and HUVECs labeled with CellTracker
TM Orange were plated on Matrigel individually or mixed at a 1:2
ratio and imaged 5 and 20 hours later. The effect of 5 mM PEG-TNYL-RAW or an equal amount of PEG control on tube formation was analyzed. The
histogram shows average tube lengths quantified from 2–3 micrographs at 5 hours for EMCs and 20 hours for HUVECs and HUVEC + EMC co-cultures
and normalized to the average for the PEG control. Error bars represent the standard error from tube length measured from 3–4 wells. Tube length in
the presence of PEG-TNYL-RAW was compared to that in the presence of PEG by one-way ANOVA and Bonferroni’s post test. ***P,0.001. PEG-TNYL-
RAW showed a trend towards decreasing tube formation in EMCs grown in Medium 200, which however did not reach significance (P=0.11 by t-test).
Scale bar=250 mM.
doi:10.1371/journal.pone.0028611.g005
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din is the most straightforward method to increase the half-life of
biotinylated TNYL-RAW and could be used to improve the
stability of the peptide for use in cell and organotypic culture
systems. It should be noted that although TNYL-RAW-Fc is
dimeric and TNYL-RAW-streptavidin is tetrameric, these forms
of the peptide remain unable to detectably activate EphB4 and
therefore retain the antagonistic function of the monomeric
peptide (unpublished data).
Covalent attachment of molecules to PEG, such as 40 KDa
branched PEG, is a widely used approach to improve water
solubility, shield from proteolytic enzymes, prevent loss through
kidney filtration and uptake by the reticuloendothelial system as
well as reduce immunogenicity [40,52,53,54,55,56]. Therefore,
PEGylation greatly prolongs in vivo circulating half-lives of peptides
and proteins and enhances their therapeutic potential without
toxic effects. Indeed, a number of drugs being evaluated in clinical
trials or already approved for human use are PEGylated
[52,57,58].
All three modified forms of TNYL-RAW retain similar high
EphB4 binding affinity and inhibitory ability as the non-modified
peptide, but have a much increased half-life. The modifications
greatly improve the resistance of TNYL-RAW to cell-derived
proteases, with essentially no degradation observed for up to two
days in PC3 cell-conditioned culture medium. Although the three
modifications also all increase TNYL-RAW half-life in the mouse
Figure 6. PEGylation increases the effectiveness of the TNYL-RAW peptide in inhibiting capillary-like tube formation by co-coltured
HUVECs and EMCs. HUVECs labeled with CellTracker
TM Orange and EMCs expressing EGFP were plated on Matrigel in complete Medium 200 at a
2:1 ratio and imaged 15 hours later. The effect of different concentrations of PEG-TNYL-RAW or TNYL-RAW on tube formation was analyzed. The
histograms show the average tube lengths for the different peptide treatments normalized to the average for the PEG or DMSO controls. Error bars
represent the standard error from 3–4 wells. Tube lengths for PEG-TNYL-RAW or TNYL-RAW were compared to the PEG or DMSO control by one-way
ANOVA and Dunnett’s post test. **P,0.001; ***P,0.001. TNYL-RAW at 20 mM showed a trend towards decreasing tube formation, which however did
not reach significance (P=0.40 by t-test). Scale bar=250 mM.
doi:10.1371/journal.pone.0028611.g006
Figure 7. PEGylated TNYL-RAW inhibits capillary sprouting in co-coltured HUVECs and EMCs. Collagen embedded spheroids generated
with HUVECs expressing mCherry, EMCs expressing EGFP or a 1:1 mixture of the two cell types were treated with 5 mM PEG-TNYL-RAW or PEG for 2
days. The number of sprouts and the cumulative sprout length in the HUVE + EMC spheroids were normalized to the average for the PEG control. The
histogram shows averages from 40–45 spheroids 6 SE. The values obtained for spheroids treated with PEG-TNYL-RAW were compared to those with
PEG control by one-way ANOVA. ***P,0.001. Scale bar=250 mM.
doi:10.1371/journal.pone.0028611.g007
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circulating half-life of ,11 hours and a 10 fold higher systemic
exposure than the other two modified forms of TNYL-RAW.
Furthermore, peptide loss appears to slow down at later times, and
,20% of the PEGylated TNYL-RAW is still present in the mouse
blood 24 hours after intravenous or intraperitoneal administra-
tion.
Conjugation of TNYL-RAW to PEG-coated micellar nanopar-
ticles has also been recently shown to increase the half-life of the
peptide in the mouse blood circulation to ,2 hours [49]. Such
nanoparticles, filled with an infrared fluorescent dye and labeled
with Indium-111, were successfully used to visualize EphB4-
expressing prostate xenograft tumors in mice by both optical
imaging and single photon emission computed tomography
(SPECT). TNYL-RAW coupled to the chelating agent DOTA
in complex with Copper-64 (
64Cu-DOTA-TNYL-RAW) has also
been recently used to image EphB4-expressing tumors using small-
animal positron emission tomography (PET) [34]. Although the
circulating half-life of
64Cu-DOTA-TNYL-RAW is much shorter
than that of the peptide attached to the nanoparticles [49], it is still
sufficient for tumor imaging, perhaps because the N-terminal
DOTA chelating group provides some protection from the
aminopeptidases present in the blood [50]. These studies support
the effectiveness of TNYL-RAW for non-invasive imaging of
EphB4-expressing tumors, which could be useful for cancer
diagnosis and to monitor the effects of anti-cancer therapies.
PEGylated TNYL-RAW inhibits EphB4 phosphorylation in
melanoma cells stimulated with ephrin-B2 even 24 hours after its
addition to cell culture medium, whereas the less stable
unmodified TNYL-RAW is ineffective after prolonged incubation
in cell culture medium. The PEGylated peptide also inhibits
tyrosine phosphorylation of EphB4 and ephrin-B2 in co-cultured
EMCs and HUVECs after a 15 hour incubation in the culture
medium. Furthermore, consistent with increased stability, PEG-
TNYL-RAW significantly inhibits endothelial-mural cell assembly
into capillary-like tubes at a concentration of less than 1 mM,
whereas unmodified TNYL-RAW does not have a significant
effect even at a concentration of 20 mM. Interestingly, even at a
concentration of 5 mM PEG-TNYL-RAW does not significantly
affect capillary-like tube formation in HUVECs or EMCs cultured
separately. These findings suggest that while inhibition of EphB4-
ephrin-B2 interaction is sufficient to disrupt the assembly of
endothelial with perivascular mesenchymal cells under the
conditions of our experiments, other Eph receptors may play a
more important role in tube formation by HUVECs and EMCs
cultured separately [21,24,59]. For example, HUVECs express
EphB2 [36], another Eph receptor that can stimulate ephrin-B2
reverse signaling and that is not targeted by the TNYL-RAW
peptide [33]. In addition, EphA2-ephrin-A1 interaction has been
shown to play a critical role in the assembly of HUVECs into tubes
[59].
The interaction between EphB4 and ephrin-B2 expressed in
endothelial and mural cells also appears to play a critical role in
capillary sprouting under the conditions of our experiments, as
suggested by the observation that in the absence of exogenously
added proangiogenic factors HUVECs and EMCs embedded as
spheroids in collagen generate capillary sprouts only when the two
cell types are cultured together, an effect that is blocked by the
addition of PEG-TNYL-RAW. Interestingly, the sprouts appear to
mostly contain EMCs, consistent with reports showing that
pericytes in some cases precede endothelial cells in the formation
of capillary sprouts [60,61,62].
These results imply that the PEGylated form of TNYL-RAW
could be used to interfere with tumor angiogenesis and other forms
of pathological angiogenesis. The ability of PEG-TNYL-RAW to
disrupt the coordinated interplay of endothelial and perivascular
mesenchymal cells suggests that this peptide could be used to: (1)
enhance the effectiveness of anti-angiogenic cancer treatments
targeting vascular endothelial growth factor (VEGF) or VEGF
receptor, which preferentially affect smaller blood vessels lacking a
perivascular cell component and (2) disrupt the remodeled blood
vessels of tumors that have recurred after anti-VEGF treatments,
which are typically stabilized by perivascular mesenchymal cells
[63,64,65,66]. Interestingly, elevated levels of ephrin-B2 have been
reported in the remodeled blood vessels of tumors that recur after
anti-angiogenic treatments [65] and the soluble extracellular
domain of EphB4 has been shown to disrupt tumor endothelial cell
coverage by mural cells in vivo [30,31]. Inhibition of EphB4-
ephrin-B2 interaction by PEG-TNYL-RAW could also be useful
to inhibit the growth of cancer cells in which EphB4-ephrin-B2
interaction promotes tumorigenesis, such as melanoma cells
[9,10,11].
Importantly, TNYL-RAW also represents a powerful tool to
investigate the role of EphB4-ephrin-B2 interaction in pathological
and physiological processes, given its selectivity for EphB4. For
instance, TNYL-RAW has been recently used to demonstrate that
ephrin-B2 has effects in endothelial cells that are independent of
interaction with EphB4 [37] and that EphB4 has effects in breast
cancer cells that are independent of interaction with ephrin-B2
[67]. For all these applications, using a form of the peptide with
improved stability, such as PEG-TNYL-RAW, will represent an
advantage by enabling long-term EphB4 inhibition in cell culture
as well as in vivo studies, and the use of substantially lower
amounts of the peptide.
Materials and Methods
Synthesis of TNYL-RAW and biotinylated TNYL-RAW
TNYL-RAW was synthesized by using solid phase Fmoc [N-(9-
fluorenyl)methoxycarbonyl] chemistry on a 433A peptide synthe-
sizer (Applied Biosystems, Foster City, CA) with a Tenta Gel S
RAM resin, as described previously for other peptides [68]. Biotin
was conjugated onto the e–amino group of a Lys attached at the C
terminus of TNYL-RAW through an aminohexanoic acid linker.
The crude peptide was purified to ,95% final purity. Alterna-
tively, TNYL-RAW at ,90% purity was obtained from Anaspec
(Fremont, CA).
Preparation of TNYL-RAW-Fc, TNYL-RAW-streptavidin and
PEG-TNYL-RAW
TNYL-RAW fused with human Fc (TNYL-RAW-Fc) was
produced by cloning a cDNA encoding the TNYL-RAW peptide
into a pcDNA3-based vector preceded by a signal peptide
sequence for secretion into the medium and followed by sequences
encoding a GSGSK linker and human Fc [69]. The TNYL-RAW-
Fc plasmid was used to transiently transfect human embryonic
kidney (HEK) 293 cells, which were expanded in DMEM with
10% fetal bovine serum (FBS) (Hyclone, Logan, UT), and then
grown for 4 days in serum-free low IgG Opti-MEM (Life
Technologies/Invitrogen). TNYL-RAW-Fc was purified from
the cell culture medium using protein A-coupled to sepharose
beads (GE Healthcare, UK).
TNYL-RAW in complex with streptavidin (TNYL-RAW-
streptavidin) was obtained by incubating biotinylated TNYL-
RAW and streptavidin (Pierce Biotechnology, Rockford, IL) at a
molar ratio of 4:1 for 30 min at 4uC in phosphate buffered saline
(PBS).
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incubating TNYL-RAW (200–500 mM) with branched 40 KDa
PEG-succinimidyl-glutarate molecules (NHS-glutaryl PEG, NOF
Corporation, Tokyo, Japan) at a 1:2 or 1:3 molar ratio in PBS for
30 min at room temperature followed by 5 hours at 4uC. The
PEGylated peptide was then dialyzed for 1.5 days at 4uC against
PBS using 5,000 MWCO microdialysis units (Pierce Biotechnol-
ogy, Rockford, IL) in order to remove peptide that may have
remained uncoupled. However, the concentration of PEG-TNYL-
RAW after dialysis was estimated assuming that essentially all the
peptide was coupled to PEG. A solution containing NHS-glutaryl
PEG that underwent all the steps described above but without the
addition of TNYL-RAW was used as control in cell-based
experiments.
Preparation of EphB4 AP and ephrin-B2 AP
Alkaline phosphatase (AP) fusion proteins were produced by
transiently transfecting the mouse EphB4 AP [70] or mouse
ephrin-B2 AP plasmids (GeneHunter, Nashville, TN) in HEK
293T cells and growing the cells in serum-free Opti-MEM
medium for 2–4 days. If necessary, the culture medium containing
the secreted AP protein was concentrated by centrifugation in
Amicon 30,000 MW cutoff filters (Millipore, Inc., Temecula, CA).
EphB4 and ephrin-B2 AP concentrations were calculated from
alkaline phosphatase activity [71].
Measurements of TNYL-RAW binding affinity
The EphB4 binding affinity of the different forms of TNYL-
RAW was measured in ELISA assays. Different concentrations of
biotinylated TNYL-RAW and TNYL-RAW-streptavidin were
incubated in TBST buffer (150 mM NaCl, 50 mM Tris-HCl,
pH 7.5 with 0.01% Tween 20) in protein A-coated wells (Pierce
Biotechnology, Rockford, IL) in which EphB4 Fc (1 mg/ml in
TBST; R&D Systems, Minneapolis, MN) had been immobilized.
Bound biotinylated TNYL-RAW was detected with horseradish
peroxidase (HRP)-conjugated streptavidin (1:2,000 dilution in
TBST, Pierce Biotechnology, Rockford, IL) and bound TNYL-
RAW-streptavidin was detected with an anti-streptavidin antibody
coupled with HRP (1:1,000 dilution in TBST, Life Technologies-
Invitrogen). Absorbance at 405 nm was measured following
incubation with 0.2 mg/ml 2,29-azino-bis(3-ethylbenzthiazoline-
6-sulfonic acid) (ABTS) (Sigma-Aldrich, Steinheim, Germany) in
citric acid as a substrate for HRP, and the absorbance in wells
without peptide was subtracted as background.
Binding of PEG-TNWL-RAW to EphB4 was measured using a
similar ELISA assay, except that Ni-NTA-coated wells (Qiagen,
Valencia, CA) were used to immobilize EphB4 Fc (which also
contains an hexa-histidine tag). The bound PEG-TNYL-RAW
was detected using 2 mg/ml AGP3 anti-PEG antibody (Academia
Sinica, Taiwan) in TBST followed by a secondary anti-mouse
IgM-HRP antibody (1:1,000 dilution in TBST, Morphosys,
Munich, Germany). Biotinylated PEG-TNYL-RAW could not
be detected using streptavidin-HRP, presumably because the
bulky PEG interferes with the binding of streptavidin to the C-
terminal biotin tag on the peptide. The absorbance from wells
without peptide was subtracted as background.
To compare the binding affinities of biotinylated TNYL-RAW
and TNYL-RAW Fc, polystyrene high binding capacity plates
(Corning, Corning, NY) were coated overnight with either 2 mg/
ml streptavidin (Pierce Biotechnology, Rockford, IL) or 10 mg/ml
anti-Fc antibody (Jackson laboratory, Sacramento, CA) diluted in
borate buffer (0.1 M boric acid, 0.1 M Na borate, pH 8.7) to
capture biotinylated TNYL-RAW and TNYL-RAW-Fc, respec-
tively. After blocking with 5 mg/ml bovine serum albumin in PBS,
different amounts of EphB4 AP in cell culture medium diluted in
TBST were added to the wells for 3 hours. Bound EphB4 AP was
detected by adding 1 mg/ml pnitrophenylphosphate (pNPP;
Pierce Biotechnology, Rockford, IL) in SEAP buffer (105 mM
diethanolamine, 0.5 mM MgC12, pH 9.8) as a substrate and
measuring the absorbance at 405 nm. The absorbance from wells
where no EphB4 AP was added was subtracted as the background.
All binding curves were analyzed using non-linear regression and
the program Prism (GraphPad Software Inc.).
Inhibition of EphB4-ephrin-B2 binding
EphB4 Fc (1 mg/ml in TBST) was immobilized in protein A-
coated plates and incubated for 3 hours with 0.02 nM ephrin-B2
AP in culture medium diluted in TBST in the presence of different
concentrations of TNYL-RAW, TNYL-RAW-Fc, TNYL-RAW-
streptavidin and PEG-TNYL-RAW. Bound ephrin-B2 AP was
quantified by adding pNPP as the substrate and measuring the
absorbance at 405 nm. Alkaline phosphatase activity from wells
where human Fc (R&D Systems, Minneapolis, MN) was added
instead of EphB4 Fc was subtracted as the background. The
binding curves were analyzed using non linear regression and the
program Prism (GraphPad Software Inc.).
Measurement of TNYL-RAW stability in cell culture
medium
PC3 prostate cancer cells were grown in RPMI 1640 medium
(Mediatech, Inc, Herndon, VA) with 10% fetal bovine serum (FBS)
(Hyclone, Logan, UT), penicillin and streptomycin. B16-F10-luc-
G5 melanoma cells (Caliper Life Sciences, Hopkinton, MA) were
grown in Eagle’s MEM with Earle’s Balanced Salts (EBSS)
(Hyclone, Logan, UT) supplemented with 10% FBS, non essential
amino acids (Hyclone, Logan, UT), L-glutamine, sodium pyruvate
(Hyclone, Logan, UT), MEM vitamin solution (Life Technologies-
Invitrogen), penicillin and streptomycin (Omega Scientific, Tar-
zana, CA). HUVECs (Cascade Biologics, Portland, OG) were
grown in Medium 200 supplemented with low serum growth
supplements (Cascade Biologics), 10% FBS, penicillin and strepto-
mycin, and fungizone (Omega Scientific, Tarzana, CA). Rat EMCs
were grown in DMEM (Mediatech, Inc, Herndon, VA) supple-
mented with 10% FBS, penicillin and streptomycin. The different
modified forms of TNYL-RAW at a concentration of 25 nM were
added to fresh medium or culture medium conditioned by the cells
for 1–4 days. The culture medium was collected after different time
periods and diluted 1:10 in ELISA wells. The amount of intact
TNYL-RAW peptide remaining was measured by using the ELISA
assays described above for measurement of bindingaffinity. In some
experiments, the peptide was incubated at 37uC with PC3 cell
conditioned mediumcollected from the cells in the absenceor in the
presence of protease inhibitors (10 mg/ml aprotinin, 5 mg/ml
pepstatin, 10 mg/ml leupeptin and 0.75 mM or phenylmethylsulfo-
nylfluoride (PMSF)).
Peptide retention in mouse blood
2.1 nmoles TNYL-RAW-Fc, 1.5 nmoles TNYL-RAW-strepta-
vidin and 6 nmoles PEG-TNYL-RAW, diluted in 150 ml sterile
PBS, were administered to C57BL/6 mice by intravenous or
intraperitoneal injection. Blood was collected from each mouse
from the orbital sinus at two time points after injection and by
cardiac puncture under Avertin anesthesia at a third time point.
These experiments were carried out in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
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(Animal Assurance Number: A-3053-1). After collection, the blood
was clotted fibrinogen, and the serum was stored at 220uC. The
different forms of TNYL-RAW in the serum were detected by
using the same ELISA assays described above for measurements of
binding affinity. The absorbance from wells incubated with mouse
serum without TNYL-RAW was subtracted as the background
and the concentration of TNYL-RAW in the blood was calculated
based on a standard curve generated using serum containing
known TNYL-RAW concentrations. The half-life of each peptide
was estimated by using non linear regression and the program
Prism (GraphPad Software Inc.). The area under the curve (AUC)
was expressed as % IDNhours/ml (where ID is the initial dose of
peptide injected) and calculated by dividing the AUC value
obtained using the program Prism by the amount of injected
peptide and multiplying by 100.
Capillary-like tube formation assays
An EMC clone expressing EGFP was generated by transducing
EMCs (a kind gift from H. Eid) with a lentiviral construct followed
by clonal selection [46]. To generate capillary-like tubes,
HUVECs (2.8610
4), EMCs (7.5610
4) or a mixture of the two
cell types (2.8610
4 HUVECs and 1.4610
4 EMCs) were grown for
5 to 20 hours in 24-well tissue culture plates (Corning, Corning,
NY) precoated with 80 ml Matrigel (BD Bioscience, San Jose, CA)
in Medium 200 or DMEM complete culture medium containing
PEG-TNYL-RAW or PEG control. In some experiments, mixed
cultures were treated with TNYL-RAW or DMSO control. The
cells were then fixed for 15 min in 4% formaldehyde in PBS and
photographed under a fluorescence microscope. Tube length was
quantified using ImageJ software.
Immunofluorescence
HUVECs, EMCs or a 2:1 mixtures of the two cell types were
cultured for 15 hours on untreated or Matrigel-coated glass coverslips
and stained with an anti-smooth muscle actin antibody (Sigma-
Aldrich, Steinheim, Germany), followed by a secondary anti-mouse
antibody conjugated with Alexa Fluor 568 (Life Technologies/
Invitrogen). To assess the effect of PEG-TNYL-RAW on ephrin-B2
phosphorylation, HUVECs and EMCs were plated at a 1:1 ratio on
glass coverslips in complete Medium 200 in the presence of PEG-
TNYL-RAW or PEG control. After 15 hours, the cells were
stimulated with 1.5 mg/ml EphB4 Fc or Fc control, which had been
preclustered with a 3 fold excess of an anti-Fc antibody for 20 min in
the continued presence of the peptide. The cells were then fixed for
1 5m i ni n4 %f o r m a l d e h y d ei nP B S ,p e r m e a b i l i z e df o r3m i ni n
0.5% Triton X-100 in TBS, and stained with anti phospho-ephrin-B
(Tyr324/329) antibody (Cell Signalling, Danvers, MA) followed by a
secondary anti-rabbit antibody conjugated with Alexa Fluor 568.
Nuclei were labeled with 49,6-diamidino-2-phenylindole (DAPI) and
the cells were photographed under a fluorescence microscope. To
quantify the amount of phosphorylated ephrin-B2, total fluorescence
intensity from 6 representative micrographs was measured using
Metamorph software (Molecular Devices) and normalized to the
number of cells in each micrograph.
Capillary sprouting assay
Spheroids were generated by seeding 750 HUVECs transduced
with a lentiviral vector encoding mCherry (GeneCopoeia, Rock-
ville, MD), EMCs expressing EGFP or a 1:1 mixture of the two cell
types in 20 ml of complete Medium 200 in non-adherent round
bottom 96 well plates (Corning, Corning, NY). The plates were
centrifuged at 160 g for 25 sec and placed in a 5% CO2 cell culture
incubator at 37uC. After 24 hours, PEG-TNYL-RAW or control
PEG were added in 5 ml FBS and the spheroids were embedded in
collagenbyaddingtoeach well20 ml of2 mg/mlneutralized rattail
collagen according to a published protocol [72]. After allowing the
collagen to polymerize for 1 hour at 37uC, complete medium
without added angiogenic factors and containing PEG-TNYL-
RAW or PEG was added on top of the collagen. The embedded
spheroidswerekept for 2 days in a 5%CO2 cell culture incubator at
37uC and photographed under a fluorescence microscope. The
number and total length of capillary sprouts originating from each
spheroid was quantified using ImageJ software.
Immunoprecipitation and immunoblotting
B16-F10-luc-G5 melanoma cells, which endogenously express
EphB4, were serum starved for 1–3 hours in Eagle’s MEM/EBSS
containing 0.5% FBS and incubated for 15 min or 24 hours with
different concentrations of PEG-TNYL-RAW. The cells were then
stimulated for 20 min with 1.5 mg/ml ephrin-B2 Fc, which had
been preclustered with a 3 fold excess of an anti-Fc antibody, in
the continued presence of the peptide. HUVECs, EMCs or a 1:1
mixture of the two cell types were plated for 20 hours in complete
medium in the presence of PEG or PEG-TNYL-RAW. Medium
200 was used for HUVECs and HUVECs and EMCs co-cultures,
DMEM was used for EMCs. The cells were lysed in modified
RIPA buffer (1% Triton X-100, 1% Na deoxycholate; 0.1% SDS;
20 mM Tris; 150 mM NaCl; 1 mM EDTA) containing 10 mM
NaF, 1 mM sodium pervanadate and protease inhibitors. Protein
concentrations were measured using the BCA protein assay kit
(Pierce Biotechnology, Rockford, IL). For immunoprecipitations,
cell lysates were incubated with 20 mg of an anti-EphB4 antibody
made to a GST fusion protein of the EphB4 SAM domain and
carboxy-terminal tail [15] immobilized on GammaBind Sepharose
beads (GE Healthcare Life Sciences). Immunoprecipitates and
lysates were probed by immunoblotting with anti-phosphotyrosine
antibody (Millipore, Inc., Temecula, CA), pan-ephrin-B antibody
(Life Technologies/Invitrogen), anti-ß-actin antibody (Sigma-
Aldrich, Steinheim, Germany), and anti-EphB4 antibody.
Supporting Information
Figure S1 The TNYL-RAW peptide is rapidly lost in cell
culture medium from different cell types. Biotinylated
TNYL-RAW was added to cell culture medium collected from
B16 melanoma cells, HUVECs and EMCs after overnight culture.
Functional (EphB4- and streptavidin-binding) peptide remaining
at the indicated times was captured in ELISA plates coated with
EphB4 Fc and detected with streptavidin-HRP.
(TIF)
Figure S2 EMCs express smooth muscle actin. EMCs
expressing EGFP were cultured on coverslips (top panels) or
coverslips coated with Matrigel (bottom panels) and stained for a-
smooth muscle actin and with DAPI to label nuclei. HUVECs
were also stained as a negative control. Scale bars=100 mM.
(TIF)
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